Hexaxim

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

1

Viread

Gilead

Phase 3

42

YF-Vax

Sanofi

Phase 3

13

Immunoglobulins

CSL Behring

Phase 3

14

Recombinant Hepatitis B Vaccine

Novartis

Phase 3

75

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

26

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

47

HEPLISAV

DDynavax Technologies Corporation

Phase 3

38

Vemlidy

Gilead

Preclinical

89

HB-AS02V

HHenogen

Phase 3

210

HBVAXPRO Vaccine

HHenogen

Phase 3

2Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Vaccine1 trial

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06736041·1,714 enrolled

Hepatitis B1 trial

Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

Completed·Sanofi·Phase 3·NCT02428491·354 enrolled

Details

Drug Info

Related News